Understanding EMPA-REG OUTCOME

Slides:



Advertisements
Similar presentations
How surgeons can find information online? Martin Hewitt International Journal of Surgery Volume 5, Issue 6, Pages (December 2007) DOI: /j.ijsu
Advertisements

Crohn's disease Prof Daniel C Baumgart, MD, Prof William J Sandborn, MD The Lancet Volume 380, Issue 9853, Pages (November 2012) DOI: /S (12)
Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled.
Pathogenesis of urinary tract infections with normal female anatomy
Volume 387, Issue 10022, Pages (March 2016)
EMPA-REG OUTCOME: The Endocrinologist's Point of View
EMPA-REG OUTCOME: The Endocrinologist's Point of View
Thank God for Richard Dawkins?
Isolated Systolic Hypertension: An Update After SPRINT
Elevated levels of various circulating amino acids (AAs) predict the development of Type 2 diabetes. In one prospective study, three branched-chain AAs.
Volume 387, Issue 10022, Pages (March 2016)
Gian Paolo Fadini, Angelo Avogaro  The Lancet Diabetes & Endocrinology 
Bart Staels, PhD  The American Journal of Medicine 
Punishment beatings and the rule of law
Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment 
Viper venom for diabetic nephropathy
Frederic Rahbari-Oskoui, MD, MS  American Journal of Kidney Diseases 
EMPA-REG OUTCOME: The Endocrinologist's Point of View
Understanding EMPA-REG OUTCOME
Natriuretic peptides and cardio-renal disease
Physical activity and prevention of type 2 diabetes
Sayed H. Naderi, BMedSci, Jonathan P. Bestwick, MSc, David S. Wald, MD 
Step Care Therapy for Hypertension in Diabetic Patients
Francesco Locatelli, Lucia Del Vecchio, Simeone Andrulli, Sara Colzani 
Franz H. Messerli, MD, Sripal Bangalore, MD, MHA 
Viper venom for diabetic nephropathy
Correction to Lancet Diabetes Endocrinol 2015; 3: 263–74
Recognition, Pathogenesis, and Treatment of Different Stages of Nephropathy in Patients With Type 2 Diabetes Mellitus  George L. Bakris, MD  Mayo Clinic.
Non-uraemic calciphylaxis with acral necrosis
INSIGHT and NORDIL The Lancet
Physiological hazards of flight at high altitude
Can famine relief meet health and hunger goals simultaneously?
Punishment beatings and the rule of law
Understanding EMPA-REG OUTCOME
The Role of the Kidney in Glucose Control
HIV myths should not be resuscitated
Late-stage research for diabetes and related NCDs receives little funding: evidence from the NIH RePORTER tool  Pascal Geldsetzer, Till Bärnighausen 
Audit-based education: a potentially effective program for improving guideline achievement in CKD patients  Moniek C.M. de Goeij, Joris I. Rotmans  Kidney.
Volume 80, Issue 9, Pages (November 2011)
Resistant Hypertension and the Pivotal Role for Mineralocorticoid Receptor Antagonists: A Clinical Update 2016  Murray Epstein, MD, Daniel A. Duprez,
Bruce Neal, Fiona Turnbull  The Lancet 
Volume 362, Pages s6-s7 (December 2003)
Correction to Lancet Diabetes Endocrinol 2015; 3: 263–74
Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled.
Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study  Tiew-Hwa K Teng, PhD, Jasper.
Confessions of a journal junkie
Telling it like it isn't: truth and lies in a post-9/11 world
Thank God for Richard Dawkins?
Seeking asylum, losing hope
Low-technology approaches
Volume 373, Issue 9668, Pages (March 2009)
The emotional journey of gestational diabetes
Volume 373, Issue 9668, Pages (March 2009)
Volume 361, Issue 9352, Pages (January 2003)
Muh Geot Wong, Vlado Perkovic  The Lancet Diabetes & Endocrinology 
David M. Charytan, John P. Forman  Kidney International 
Age-dependent care and long-term (20year) mortality of 14,434 myocardial infarction patients: Changes from 1985 to 2008  Sjoerd T. Nauta, Jaap W. Deckers,
Angiotensin converting enzyme inhibitor captopril modifies conditioned place preference induced by morphine and morphine withdrawal signs in rats  Hojjatallah.
The future of renoprotection: Frustration and promises
Isolated Systolic Hypertension: An Update After SPRINT
Comparative Superiority of ACE Inhibitors Over Angiotensin Receptor Blockers for People With CKD: Does It Matter?  Dimitris Mavridis, PhD  American Journal.
Craig S. Stump, MD, PhD, Marc T. Hamilton, PhD, James R. Sowers, MD 
Volume 73, Issue 5, Pages (March 2008)
Volume 68, Issue 5, Pages (November 2005)
Potential antitumour activity of pasireotide on pituitary tumours in acromegaly  Eva C Coopmans, Aart J van der Lely, Joppe J Schneiders, Sebastian J C.
Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: Pathophysiology and indications 
Natriuretic peptides and cardio-renal disease
Schematic of the interaction between the renin-angiotensin-aldosterone system (RAAS) system and the natriuretic peptides and how the RAAS modulators and.
Proteinuria and hypertension with tyrosine kinase inhibitors
Renin-angiotensin-aldosterone-system inhibition is safe in the preoperative period surrounding carotid endarterectomy  Andrea M. Steely, MD, Peter W.
Presentation transcript:

Understanding EMPA-REG OUTCOME Marcel H A Muskiet, Daniël H van Raalte, Erik JM van Bommel, Mark M Smits, Lennart Tonneijck  The Lancet Diabetes & Endocrinology  Volume 3, Issue 12, Pages 928-929 (December 2015) DOI: 10.1016/S2213-8587(15)00424-6 Copyright © 2015 Elsevier Ltd Terms and Conditions

Figure Rationale for potential benefit of combined SGLT2 and RAAS-inhibition in type 2 diabetes. SGLT2 inhibitors in addition to ACE inhibition or angiotensin-receptor blockade might favour improved cardiovascular outcomes by increasing AT2-receptor and Mas-receptor activation. SGLT2=sodium-glucose cotransporter-2. ACE=angiotensin-converting enzyme. ACE2=angiotensin-converting enzyme 2. Ang I=angiotensin-I. Ang II=angiotensin-II. ARB=angiotensin-receptor blocker. AT1=type-1 angiotensin II receptor. AT2=type-2 angiotensin-II receptor. NEP=neutral endopeptidase. RAAS=renin-angiotensin-aldosterone-system. The Lancet Diabetes & Endocrinology 2015 3, 928-929DOI: (10.1016/S2213-8587(15)00424-6) Copyright © 2015 Elsevier Ltd Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.